- Home
- RVPH vs NRXP Comparison
RVPH vs NRXP Comparison
Compare RVPH & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- NRXP
- Stock Information
- Founded
- RVPH 2006
- NRXP 2015
- Country
- RVPH United States
- NRXP United States
- Employees
- RVPH N/A
- NRXP N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- NRXP Health Care
- Exchange
- RVPH Nasdaq
- NRXP Nasdaq
- Market Cap
- RVPH 32.8M
- NRXP 32.6M
- IPO Year
- RVPH N/A
- NRXP N/A
- Fundamental
- Price
- RVPH $0.40
- NRXP $3.24
- Analyst Decision
- RVPH Strong Buy
- NRXP Strong Buy
- Analyst Count
- RVPH 5
- NRXP 4
- Target Price
- RVPH $9.00
- NRXP $28.50
- AVG Volume (30 Days)
- RVPH 3.4M
- NRXP 212.8K
- Earning Date
- RVPH 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- RVPH N/A
- NRXP N/A
- EPS Growth
- RVPH N/A
- NRXP N/A
- EPS
- RVPH N/A
- NRXP N/A
- Revenue
- RVPH N/A
- NRXP N/A
- Revenue This Year
- RVPH N/A
- NRXP N/A
- Revenue Next Year
- RVPH N/A
- NRXP N/A
- P/E Ratio
- RVPH N/A
- NRXP N/A
- Revenue Growth
- RVPH N/A
- NRXP N/A
- 52 Week Low
- RVPH $0.30
- NRXP $1.10
- 52 Week High
- RVPH $4.28
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- RVPH 33.44
- NRXP 53.62
- Support Level
- RVPH $0.35
- NRXP $2.90
- Resistance Level
- RVPH $0.83
- NRXP $3.53
- Average True Range (ATR)
- RVPH 0.06
- NRXP 0.20
- MACD
- RVPH -0.01
- NRXP -0.04
- Stochastic Oscillator
- RVPH 17.36
- NRXP 58.73
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.